Culper Research vs Cerebras: A Neutral Engineering-Driven View
Cerebras’ alleged electromigration issues hinge on temperature and voltage limits, not total power draw, while thermal variation and BallWire power integrity remain concerns.
Cerebras’ alleged electromigration issues hinge on temperature and voltage limits, not total power draw, while thermal variation and BallWire power integrity remain concerns.
$PFBX- $TRMK cash is only a phone call away, Chevis https://t.co/q6TsUc9NCO
Holy sht, $MRVL is in the final stages of a deal to acquire $LITE. Attempting to vertically integrate the most supply constrained chokepoints… with lasers. Is very big brain if they pull it off and suddenly makes other laser players more strategically valuable. https://t.co/61vfIIsBRw
Has $ADYEN ever not puked on earnings? It feels like one of those $SNAP esque stocks that drops 10% every quarter, steadily climbs back as sentiment recovers just to puke 10% again.
Depends on the tenant, but I use a 10% cap (10x) for $CORZ's CoreWeave sites. I think the cap rate should be lower given CoreWeave funded the capex, and it sits in CORZ's facilities under CORZ's first lien, but appreciate the market won’t necessarily price at its real “fair value”
$MRVL for $LITE absolutely meets the test mentioned below. https://t.co/53nmZnoYQ9
*MARVELL IS SAID IN ADVANCED TALKS TO BUY LUMENTUM HOLDINGS What the fuck???? $MRVL $LITE
*MARVELL IS SAID IN ADVANCED TALKS TO BUY LUMENTUM HOLDINGS $LITE
Cerebras relies on OpenAI for almost all of its $25 billion backlog while renting AI capacity, raising questions over its semiconductor…
Cigna faces PBM margin pressure as employer fee demands and Signature transition costs outweigh specialty-drug growth, limiting profit…
Enova’s Q3 2026 revenue exceeded $1 billion as originations rose 31%, while its failed Grasshopper Bank bid drove a 23% one-day stock…
Vertiv beat Q3 revenue guidance by $460 million, grew organic sales 55%, and raised full-year revenue guidance by $650 million to a $14.65…
EQT moved to Distribute at $56.29 after Q3 revenue fell 9.6%; a 44% trailing free-cash-flow margin signals cycle risk despite lower debt…
Innodata shares fell 25% to $44.74 after India Today reported 550 job cuts in India.
GFL’s take-private structure hinges on BC Partners rolling 60% of its stake to preserve debt portability under the 40% permitted-holder…
Lumentum’s 2027 optical-chip expansion, 200G EML and CW capacity, silicon-photonics roadmap, pricing and 3.2T module prospects face…
AppFolio grew third-quarter revenue 19% as Realm-X AI agents gained adoption, lifting guidance to $1.122 billion to $1.127 billion.
Neoclouds face tighter debt financing as AI infrastructure capex outruns cash flow, leaving cash-burning GPU providers more exposed than…
UHS · long Universal Health Services is a profitable hospital operator whose $146 share price over-discounts an earnings-collapse scenario.
Veeva beat its $905 million revenue guide with $928 million, up 17.6%, while subscription growth accelerated and GAAP EBIT margin reached…
Bloom Energy’s 80x forward earnings valuation relies on concentrated megaprojects, sustained AI data-center power demand and continued…
Colombia and Venezuela are opening oil sectors to outside producers, as Venezuela offers producing blocks and Ecopetrol seeks capital for…
Meta’s $18 billion teen-addiction settlement makes $5.3 billion contingent on YouTube and TikTok adopting matching restrictions, while…
StandardAero’s exclusive engine licenses and LEAP aftermarket position underpin a projected rise in LEAP revenue from $100 million in 2025…
TSOH Weekly Roundup tracks Dick’s Sporting Goods’ Foot Locker setback and Brown-Forman’s internal debate over a potential Pernod Ricard…
QXO is building a North American construction-products distributor through Beacon, Kodiak and TopBuild, targeting $18.1 billion of combined…
Higher rates could compress equity multiples and raise AI data center lease costs, while UWMC and Cogent raise questions about CEO-driven…
Biohaven’s $795 million global opakalim licensing deal with SK Biopharmaceuticals boosts cash, lowers R&D spending and extends its funding…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.